STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation

Biochemical and Biophysical Research Communications

Volumn 478, Issue 4, 2016, Pages 1764-1771

  Takashima, Ken ^a   Takeda, Yohei ^a   Oshiumi, Hiroyuki ^a   Shime, Hiroaki ^a   Okabe, Masaru ^b   Ikawa, Masahito ^b   Matsumoto, Misako ^a   Seya, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Antitumor immunity; B16 cell line; Interferon; NK cells; STING

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 33; MEMBRANE PROTEIN; PROTEIN STING; RANTES; UNCLASSIFIED DRUG; BETA INTERFERON; MPYS PROTEIN, MOUSE; NUCLEAR MATRIX PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; RAE1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HOST CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MELANOMA B16; MELANOMA CELL LINE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL5; CHEMOKINE CXCL10; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERFERON-BETA; INTERLEUKIN-33; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEAR MATRIX-ASSOCIATED PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR BURDEN;

EID: 84991594418     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.09.021     Document Type: Article

References (24)

1. [1] Barber, G.N., STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15 (2015), 760–770, 10.1038/nri3921.
2. [2] Corrales, L., McWhirter, S.M., Dubensky, T.W., Gajewski, T.F., The host STING pathway at the interface of cancer and immunity. J. Clin. Invest. 126 (2016), 2404–2411, 10.1172/JCI86892.
3. [3] Yoshida, H., Okabe, Y., Kawane, K., Fukuyama, H., Nagata, S., Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat. Immunol. 6 (2005), 49–56, 10.1038/ni1146.
4. [4] Shen, Y.J., Le Bert, N., Chitre, A.A., Koo, C.X., Nga, X.H., Ho, S.S.W., et al. Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells. Cell Rep. 11 (2015), 460–473, 10.1016/j.celrep.2015.03.041.
5. [5] Ho, S.S.W., Zhang, W.Y.L., Tan, N.Y.J., Khatoo, M., Suter, M.A., Tripathi, S., et al. The DNA structure-specific endonuclease MUS81 mediates DNA sensor STING-dependent host rejection of prostate cancer cells. Immunity 44 (2016), 1177–1189, 10.1016/j.immuni.2016.04.010.
6. [6] Seya, T., Akazawa, T., Uehori, J., Matsumoto, M., Azuma, I., Toyoshima, K., Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res. 23 (2003), 4369–4376.
7. [7] Cerwenka, A., Lanier, L.L., NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61 (2003), 335–343.
8. [8] Masuda, H., Saeki, Y., Nomura, M., Shida, K., Matsumoto, M., Ui, M., et al. High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-“pan” RAE-1 antibody confer tumor susceptibility to NK cells. Biochem. Biophys. Res. Commun. 290 (2002), 140–145, 10.1006/bbrc.2001.6165.
9. [9] Temizoz, B., Kuroda, E., Ohata, K., Jounai, N., Ozasa, K., Kobiyama, K., et al. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur. J. Immunol. 45 (2015), 1159–1169, 10.1002/eji.201445132.
10. [10] Nakamura, T., Miyabe, H., Hyodo, M., Sato, Y., Hayakawa, Y., Harashima, H., Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J. Control Release 216 (2015), 149–157, 10.1016/j.jconrel.2015.08.026.
11. [11] Suzuki, T., Oshiumi, H., Miyashita, M., Aly, H.H., Matsumoto, M., Seya, T., Cell type-specific subcellular localization of phospho-TBK1 in response to cytoplasmic viral DNA. PLoS ONE, 8, 2013, e83639, 10.1371/journal.pone.0083639.
12. [12] Akazawa, T., Ebihara, T., Okuno, M., Okuda, Y., Shingai, M., Tsujimura, K., et al. Antitumor NK activation induced by the toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. 104 (2007), 252–257, 10.1073/pnas.0605978104.
13. [13] Gao, X., Wang, X., Yang, Q., Zhao, X., Wen, W., Li, G., et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J. Immunol. 194 (2015), 438–445, 10.4049/jimmunol.1401344.
14. [14] Wendel, M., Galani, I.E., Suri-Payer, E., Cerwenka, A., Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 68 (2008), 8437–8445, 10.1158/0008-5472.CAN-08-1440.
15. [15] Lavergne, E., Combadière, C., Iga, M., Boissonnas, A., Bonduelle, O., Maho, M., et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J. Immunol. 173 (2004), 3755–3762.
16. [16] Demaria, O., De Gassart, A., Coso, S., Gestermann, N., Di Domizio, J., Flatz, L., et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl. Acad. Sci. U.S.a. 112 (2015), 15408–15413, 10.1073/pnas.1512832112.
17. [17] Seya, T., Kasamatsu, J., Azuma, M., Shime, H., Matsumoto, M., Natural killer cell activation secondary to innate pattern sensing. J. Innate Immun. 3 (2011), 264–273, 10.1159/000326891.
18. [18] Lam, A.R., Le Bert, N., Ho, S.S.W., Shen, Y.J., Tang, M.L.F., Xiong, G.M., et al. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res. 74 (2014), 2193–2203, 10.1158/0008-5472.CAN-13-1703.
19. [19] Shime, H., Kojima, A., Maruyama, A., Saito, Y., Oshiumi, H., Matsumoto, M., et al. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J. Innate Immun. 6 (2014), 293–305, 10.1159/000355126.
20. [20] Fitzgerald, K.A., Woo, S.-R., Fuertes, M.B., Corrales, L., Spranger, S., Spranger, S., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842, 10.1016/j.immuni.2014.10.017.
21. [21] Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41 (2014), 843–852, 10.1016/j.immuni.2014.10.019.
22. [22] Wang, Z., Celis, E., STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol. Immunother. 64 (2015), 1057–1066, 10.1007/s00262-015-1713-5.
23. [23] Matsumoto, M., Tatematsu, M., Nishikawa, F., Azuma, M., Ishii, N., Morii-Sakai, A., et al. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat. Comms, 6, 2015, 6280, 10.1038/ncomms7280.
24. [24] Negishi, H., Miki, S., Sarashina, H., Taguchi-Atarashi, N., Nakajima, A., Matsuki, K., et al. Essential contribution of IRF3 to intestinal homeostasis and microbiota-mediated Tslp gene induction. Proc. Natl. Acad. Sci. U.S.a. 109 (2012), 21016–21021, 10.1073/pnas.1219482110.